ME02356B - Inhibitor bromodomena benzodiazepina - Google Patents
Inhibitor bromodomena benzodiazepinaInfo
- Publication number
- ME02356B ME02356B MEP-2016-52A MEP5216A ME02356B ME 02356 B ME02356 B ME 02356B ME P5216 A MEP5216 A ME P5216A ME 02356 B ME02356 B ME 02356B
- Authority
- ME
- Montenegro
- Prior art keywords
- 6alkyl
- compound
- pharmaceutically acceptable
- acceptable salt
- halo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- -1 carbocyclylC1-4alkyl Chemical group 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004452 carbocyclyl group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0919433A GB0919433D0 (en) | 2009-11-05 | 2009-11-05 | Novel compounds |
| GBGB1010509.6A GB201010509D0 (en) | 2010-06-22 | 2010-06-22 | Novel compounds |
| PCT/EP2010/061518 WO2011054553A1 (en) | 2009-11-05 | 2010-08-06 | Benzodiazepine bromodomain inhibitor |
| GBGB1014231.3A GB201014231D0 (en) | 2010-08-25 | 2010-08-25 | Novel compounds |
| PCT/EP2010/066697 WO2011054845A1 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
| EP10773325.5A EP2496582B1 (en) | 2009-11-05 | 2010-11-03 | Benzodiazepine bromodomain inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02356B true ME02356B (me) | 2016-06-20 |
Family
ID=43969589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-52A ME02356B (me) | 2009-11-05 | 2010-11-03 | Inhibitor bromodomena benzodiazepina |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9102677B2 (enExample) |
| EP (2) | EP3050885B1 (enExample) |
| JP (3) | JP5702396B2 (enExample) |
| KR (1) | KR20120097508A (enExample) |
| CN (1) | CN102781943B (enExample) |
| AU (1) | AU2010317096B2 (enExample) |
| BR (1) | BR112012010705A2 (enExample) |
| CA (1) | CA2779423C (enExample) |
| CY (1) | CY1117424T1 (enExample) |
| DK (1) | DK2496582T3 (enExample) |
| EA (1) | EA023441B1 (enExample) |
| ES (2) | ES2564318T3 (enExample) |
| HK (1) | HK1221221A1 (enExample) |
| HR (1) | HRP20160253T1 (enExample) |
| HU (1) | HUE026967T2 (enExample) |
| IL (2) | IL219253A (enExample) |
| ME (1) | ME02356B (enExample) |
| MX (1) | MX341212B (enExample) |
| PL (1) | PL2496582T3 (enExample) |
| RS (1) | RS54645B1 (enExample) |
| SI (1) | SI2496582T1 (enExample) |
| SM (1) | SMT201600104B (enExample) |
| WO (1) | WO2011054845A1 (enExample) |
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170091770A (ko) | 2006-07-10 | 2017-08-09 | 파이온 유케이 리미티드 | 속효형 벤조디아제핀 염 및 이의 중합체 형태 |
| BR112012010705A2 (pt) * | 2009-11-05 | 2016-03-29 | Glaxosmithkline Llc | composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| CA2799403C (en) | 2010-05-14 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| EP2571875A4 (en) | 2010-05-14 | 2013-10-30 | Dana Farber Cancer Inst Inc | CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF |
| PL2571503T3 (pl) | 2010-05-14 | 2015-06-30 | Dana Farber Cancer Inst Inc | Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń |
| EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| EP2721031B1 (en) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| GB201114103D0 (en) * | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033268A2 (en) * | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| DE102011082013A1 (de) * | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| EP2838881B1 (en) | 2012-04-20 | 2018-08-08 | AbbVie Inc. | Isoindolone derivatives |
| SI2852389T1 (en) * | 2012-05-22 | 2018-02-28 | Paion Uk Limited | Compositions comprising short-acting benzodiazepines |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| EP2864336B1 (en) | 2012-06-06 | 2016-11-23 | Constellation Pharmaceuticals, Inc. | Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof |
| WO2013185284A1 (en) | 2012-06-12 | 2013-12-19 | Abbott Laboratories | Pyridinone and pyridazinone derivatives |
| KR20150042231A (ko) | 2012-08-16 | 2015-04-20 | 글락소스미스클라인 엘엘씨 | 소세포폐암을 치료하기 위한 벤조디아제핀 |
| EA201590356A1 (ru) | 2012-08-16 | 2015-07-30 | Байер Фарма Акциенгезельшафт | 2,3-бензодиазепины |
| ES2625959T3 (es) * | 2012-09-28 | 2017-07-21 | Bayer Pharma Aktiengesellschaft | 5-Aril-triazolo-azepinas inhibidoras de la proteína BET |
| US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
| AR094963A1 (es) | 2013-03-04 | 2015-09-09 | Ono Pharmaceutical Co | Reacción de oxidación excelente en el índice de conversión |
| WO2014164780A1 (en) * | 2013-03-11 | 2014-10-09 | Abbvie Inc. | Fused tetracyclic bromodomain inhibitors |
| JP6401773B2 (ja) | 2013-03-11 | 2018-10-10 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法 |
| EP2970330B1 (en) * | 2013-03-12 | 2019-04-17 | AbbVie Inc. | Tetracyclic bromodomain inhibitors |
| US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| WO2014159837A1 (en) | 2013-03-14 | 2014-10-02 | Convergene Llc | Methods and compositions for inhibition of bromodomain-containing proteins |
| CA2903881C (en) | 2013-03-15 | 2021-05-18 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| EA027139B1 (ru) | 2013-04-26 | 2017-06-30 | Бейджин, Лтд. | Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны |
| CN103202815B (zh) * | 2013-05-05 | 2014-09-24 | 李友香 | 治疗精神疾病的注射剂 |
| CN104146970A (zh) * | 2013-05-05 | 2014-11-19 | 王元青 | 治疗精神疾病的冻干粉针剂 |
| CA2915622C (en) | 2013-06-21 | 2020-08-18 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
| US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
| WO2015013635A2 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| US9855271B2 (en) | 2013-07-31 | 2018-01-02 | Zenith Epigenetics Ltd. | Quinazolinones as bromodomain inhibitors |
| WO2015070020A2 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| GB201320994D0 (en) * | 2013-11-28 | 2014-01-15 | Univ Dundee | Enzyme function probes |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| MX2016009976A (es) | 2014-01-31 | 2016-11-15 | Dana Farber Cancer Inst Inc | Derivados de diazepam y sus usos. |
| EP3105232B1 (en) | 2014-02-10 | 2019-08-28 | Concert Pharmaceuticals Inc. | Substituted triazolobenzodiazepines |
| CN106456653A (zh) | 2014-02-28 | 2017-02-22 | 腾沙治疗公司 | 高胰岛素血症相关病症的治疗 |
| CA2940554A1 (en) | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| EP3129378B1 (en) * | 2014-04-09 | 2019-06-26 | Kainos Medicine, Inc. | Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer |
| DK3674302T3 (da) | 2014-04-23 | 2023-04-03 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner |
| CA2952526A1 (en) * | 2014-06-18 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-protein inhibiting 3,4-dihydropyrido[2,3-b]pyrazinones with meta-substituted aromatic amino- or ether groups |
| ES2725928T3 (es) | 2014-06-20 | 2019-09-30 | Constellation Pharmaceuticals Inc | Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida |
| CA2955077A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| WO2016022902A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| EP3194406B8 (en) | 2014-09-15 | 2021-03-31 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
| EP3201199A1 (en) * | 2014-10-02 | 2017-08-09 | Glaxosmithkline Intellectual Property (No. 2) Limited | Compound |
| MX376748B (es) | 2014-10-27 | 2025-03-07 | Tensha Therapeutics Inc | Inhibidores del bromodominio. |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| HK1245248B (en) | 2014-12-11 | 2020-05-15 | 恒翼生物医药(上海)股份有限公司 | Substituted heterocycles as bromodomain inhibitors |
| HK1245247A1 (zh) | 2014-12-17 | 2018-08-24 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| EP3262045A1 (en) | 2015-02-27 | 2018-01-03 | The Regents of The University of Michigan | 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| SMT202100593T1 (it) | 2015-03-31 | 2021-11-12 | Enanta Pharm Inc | Derivati degli acidi biliari come agonisti di fxr/tgr5 e metodi per il loro uso |
| WO2016171470A1 (en) * | 2015-04-21 | 2016-10-27 | Kainos Medicine, Inc. | Bromodomain-inhibiting compounds and methods to prevent or treat a cancer |
| WO2016196065A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2016203335A1 (en) | 2015-06-18 | 2016-12-22 | Pfizer Inc. | Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors |
| JP2018520124A (ja) | 2015-06-26 | 2018-07-26 | テンシャ セラピューティクス，インコーポレイテッド | Ｎｕｔ正中線癌の治療 |
| JP6765622B2 (ja) * | 2015-07-17 | 2020-10-07 | 日本光電工業株式会社 | 救命支援装置 |
| PT3324977T (pt) | 2015-07-22 | 2022-10-14 | Enanta Pharm Inc | Derivados de benzodiazepina como inibidores de vsr |
| JP2018526424A (ja) | 2015-09-11 | 2018-09-13 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用 |
| KR20180049058A (ko) | 2015-09-11 | 2018-05-10 | 다나-파버 캔서 인스티튜트 인크. | 시아노 티에노트리아졸로디아제핀 및 그의 용도 |
| AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
| CN114957291A (zh) | 2015-11-25 | 2022-08-30 | 达纳-法伯癌症研究所股份有限公司 | 二价溴结构域抑制剂及其用途 |
| CN106892924B (zh) * | 2015-12-17 | 2021-01-08 | 四川科伦博泰生物医药股份有限公司 | 短效苯并二氮*衍生物、其制备方法及其用途 |
| US20170226129A1 (en) | 2016-01-15 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| AU2017219627B2 (en) | 2016-02-15 | 2021-08-05 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| AU2017246453A1 (en) | 2016-04-06 | 2018-11-08 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| SG11201808729WA (en) | 2016-04-12 | 2018-11-29 | Univ Michigan Regents | Bet protein degraders |
| BR112018071216A2 (pt) | 2016-04-15 | 2019-02-05 | Abbvie Inc | inibidores de bromodomínios |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
| DE102017005089A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substitulerte 3,4-Dihydrochinoxalin-2(1H)-one |
| CA3220957A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
| CN107629057B (zh) * | 2016-07-19 | 2020-03-27 | 上海勋和医药科技有限公司 | Bet蛋白抑制剂及其应用 |
| EP3490552B1 (en) | 2016-07-26 | 2022-11-23 | University of Southern California | Selective bromodomain inhibition of fungal bdf1 |
| US11466028B2 (en) | 2016-09-13 | 2022-10-11 | The Regents Of The University Of Michigan | Fused 1,4-oxazepines as BET protein degraders |
| CN110072866A (zh) | 2016-09-13 | 2019-07-30 | 密执安大学评议会 | 作为bet蛋白降解剂的稠合的1,4-二氮杂* |
| BR112019006651A2 (pt) | 2016-10-04 | 2019-07-02 | Enanta Pharm Inc | análogos de isoxazol como agonistas de fxr e métodos de uso do mesmo |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| US20190284192A1 (en) | 2016-11-10 | 2019-09-19 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof |
| WO2018129287A1 (en) * | 2017-01-06 | 2018-07-12 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as rsv inhibitors |
| EP3577120A1 (en) | 2017-02-03 | 2019-12-11 | The Regents of The University of Michigan | Fused 1,4-diazepines as bet bromodomain inhibitors |
| JP7076459B2 (ja) | 2017-02-16 | 2022-05-27 | エナンタ ファーマシューティカルズ インコーポレイテッド | ベンゾジアゼピン誘導体の製造プロセス |
| CN108727380A (zh) * | 2017-04-13 | 2018-11-02 | 中国科学院上海药物研究所 | 一种brd4抑制剂及其制备和应用 |
| CN110418791B (zh) * | 2017-04-28 | 2022-07-01 | 四川科伦博泰生物医药股份有限公司 | 包含苯并二氮䓬类化合物的注射用组合物及其制备方法 |
| CN108948018B (zh) * | 2017-05-17 | 2021-03-30 | 四川科伦博泰生物医药股份有限公司 | 苯并二氮*衍生物及其盐和相关晶体形式、制备方法和用途 |
| US10752598B2 (en) | 2017-06-07 | 2020-08-25 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as RSV inhibitors |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| US10851115B2 (en) | 2017-06-30 | 2020-12-01 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| WO2019055444A1 (en) | 2017-09-13 | 2019-03-21 | The Regents Of The University Of Michigan | DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS |
| US11312726B2 (en) * | 2017-09-22 | 2022-04-26 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Thienodiazepine derivatives and application thereof |
| US10881666B2 (en) | 2017-09-29 | 2021-01-05 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as RSV inhibitors |
| WO2019094920A1 (en) | 2017-11-13 | 2019-05-16 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as rsv inhibitors |
| US10501422B2 (en) | 2017-11-13 | 2019-12-10 | Enanta Pharmaceuticals, Inc. | Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10975094B2 (en) | 2018-04-11 | 2021-04-13 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| TWI888359B (zh) * | 2018-09-11 | 2025-07-01 | 瑞士商赫孚孟拉羅股份公司 | 噻吩并－三唑并－二氮呯醋酸酯 |
| JP7292400B2 (ja) * | 2019-03-07 | 2023-06-16 | メッドシャイン ディスカバリー インコーポレイテッド | ＢＥＴ Ｂｒｏｍｏｄｏｍａｉｎタンパク質の阻害とＰＤ－Ｌ１遺伝子の調節の両方の効果を持つ化合物 |
| PH12021552201A1 (en) | 2019-03-18 | 2022-05-30 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| US11179400B2 (en) | 2019-04-09 | 2021-11-23 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| US11572367B2 (en) | 2019-10-04 | 2023-02-07 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| PT116050B (pt) * | 2020-01-09 | 2022-06-15 | Hovione Farm S A | Conjugados fármaco-ligando e inibidores das proteínas da família bromodomínio e domínio extraterminal -(bet) modificados |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| WO2021175432A1 (en) | 2020-03-04 | 2021-09-10 | Boehringer Ingelheim International Gmbh | Method for administration of an anti cancer agent |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CA3185149A1 (en) | 2020-06-23 | 2021-12-30 | Genentech, Inc. | Macrocyclic compounds and methods of use thereof |
| WO2022010882A1 (en) | 2020-07-07 | 2022-01-13 | Enanta Pharmaceuticals, Inc, | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| GB202016977D0 (en) | 2020-10-26 | 2020-12-09 | In4Derm Ltd | Compounds |
| CN112358483A (zh) * | 2020-11-09 | 2021-02-12 | 中国药科大学 | 一类新型苯并二氮*类化合物、其制备方法及其用途 |
| CN114456171A (zh) * | 2020-11-09 | 2022-05-10 | 中国药科大学 | 一类用于镇静催眠的苯并二氮䓬类药物、其制备方法及应用 |
| US11945830B2 (en) | 2021-02-26 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| AU2022303310A1 (en) | 2021-06-29 | 2024-02-08 | Tay Therapeutics Limited | Pyrrolopyridone derivatives useful in the treatment of cancer |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| EP4511119A1 (en) | 2022-04-19 | 2025-02-26 | Nuevolution A/S | Compounds active towards bromodomains |
| US12162857B2 (en) | 2022-04-27 | 2024-12-10 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| EP4558224A1 (en) | 2022-07-21 | 2025-05-28 | Tay Therapeutics Limited | Pyrroles and imidazoles as bet protein inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1152066A (en) | 1980-02-08 | 1983-08-16 | Hoffmann-La Roche Limited | Benzodiazepine derivatives |
| DE3610848A1 (de) * | 1986-04-01 | 1987-10-15 | Boehringer Ingelheim Kg | Neue 1,4-diazepine |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| US5593988A (en) | 1991-10-11 | 1997-01-14 | Yoshitomi Pharmaceutical Industries, Ltd. | Therapeutic agent for osteoporosis and diazepine compound |
| JPH06128257A (ja) | 1992-10-13 | 1994-05-10 | Yoshitomi Pharmaceut Ind Ltd | ピリドジアゼピン化合物 |
| WO1995014694A1 (en) | 1993-11-22 | 1995-06-01 | Merck & Co., Inc. | Benzodiazepines |
| US5807850A (en) | 1994-11-18 | 1998-09-15 | Japan Tobacco, Inc. | Therapeutic agent for osteoporosis and triazepine compound |
| JP2622673B2 (ja) * | 1994-11-18 | 1997-06-18 | 日本たばこ産業株式会社 | 骨粗鬆症治療薬およびトリアゼピン化合物 |
| IL127516A0 (en) * | 1996-06-12 | 1999-10-28 | Japan Tobacco Inc | A cytokine production inhibitor |
| AU716490B2 (en) | 1996-09-13 | 2000-02-24 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compounds and pharmaceutical use thereof |
| JPH11228576A (ja) * | 1997-12-10 | 1999-08-24 | Japan Tobacco Inc | アポトーシス抑制剤 |
| US6916995B2 (en) | 2003-02-25 | 2005-07-12 | Broadcom Corporation | Optimization of routing layers and board space requirements for ball grid array package implementations including single and multi-layer routing |
| PL1699512T3 (pl) | 2003-11-03 | 2012-11-30 | Glaxo Group Ltd | Urządzenie do dozowania płynów |
| CN1739788A (zh) | 2004-03-31 | 2006-03-01 | 新加坡国立大学 | Trip－br功能的调节和治疗增殖性紊乱的方法 |
| GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
| EP1887008B1 (en) | 2005-05-30 | 2021-04-21 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compound and a medicinal use thereof |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| CA2710740C (en) * | 2007-12-28 | 2016-07-19 | Shinji Miyoshi | Thienotriazolodiazepine compound as antitumor agent |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| BR112012010705A2 (pt) * | 2009-11-05 | 2016-03-29 | Glaxosmithkline Llc | composto, composição farmacêutica, produto farmacêutico combinado, uso de um composto, e, métodos para tratar uma doença ou condição, e para inibir um bromodomínio |
| ME02360B (me) * | 2009-11-05 | 2016-06-20 | Glaxosmithkline Llc | Inhibitor bromodomena benzodiazepina |
-
2010
- 2010-11-03 BR BR112012010705A patent/BR112012010705A2/pt not_active Application Discontinuation
- 2010-11-03 SI SI201031143T patent/SI2496582T1/sl unknown
- 2010-11-03 HR HRP20160253TT patent/HRP20160253T1/hr unknown
- 2010-11-03 AU AU2010317096A patent/AU2010317096B2/en not_active Ceased
- 2010-11-03 EA EA201290184A patent/EA023441B1/ru not_active IP Right Cessation
- 2010-11-03 MX MX2012005296A patent/MX341212B/es active IP Right Grant
- 2010-11-03 ES ES10773325.5T patent/ES2564318T3/es active Active
- 2010-11-03 PL PL10773325T patent/PL2496582T3/pl unknown
- 2010-11-03 HU HUE10773325A patent/HUE026967T2/en unknown
- 2010-11-03 CN CN201080060697.1A patent/CN102781943B/zh not_active Expired - Fee Related
- 2010-11-03 DK DK10773325.5T patent/DK2496582T3/en active
- 2010-11-03 EP EP16152464.0A patent/EP3050885B1/en active Active
- 2010-11-03 ES ES16152464.0T patent/ES2654423T3/es active Active
- 2010-11-03 ME MEP-2016-52A patent/ME02356B/me unknown
- 2010-11-03 WO PCT/EP2010/066697 patent/WO2011054845A1/en not_active Ceased
- 2010-11-03 EP EP10773325.5A patent/EP2496582B1/en active Active
- 2010-11-03 CA CA2779423A patent/CA2779423C/en not_active Expired - Fee Related
- 2010-11-03 KR KR1020127014635A patent/KR20120097508A/ko not_active Ceased
- 2010-11-03 RS RS20160190A patent/RS54645B1/sr unknown
- 2010-11-03 US US13/504,971 patent/US9102677B2/en active Active
- 2010-11-03 JP JP2012537381A patent/JP5702396B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-18 IL IL219253A patent/IL219253A/en active IP Right Grant
-
2015
- 2015-02-19 JP JP2015030132A patent/JP2015143232A/ja active Pending
- 2015-06-25 IL IL239625A patent/IL239625B/en active IP Right Grant
- 2015-06-29 US US14/753,326 patent/US9598420B2/en active Active
-
2016
- 2016-03-18 CY CY20161100231T patent/CY1117424T1/el unknown
- 2016-04-13 SM SM201600104T patent/SMT201600104B/xx unknown
- 2016-08-05 HK HK16109359.8A patent/HK1221221A1/en unknown
- 2016-09-23 JP JP2016185487A patent/JP2017039738A/ja active Pending
-
2017
- 2017-02-07 US US15/426,294 patent/US20170145021A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02356B (me) | Inhibitor bromodomena benzodiazepina | |
| CA2455768A1 (en) | Antitumoral analogs of et-736 | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2012500260A5 (enExample) | ||
| RU2014121090A (ru) | Модуляторы рецептора нмда и их применение | |
| EA200100476A1 (ru) | Новые сложные эфиры, полученные из замещенных фенилциклогексилпроизводных | |
| MX2007003648A (es) | Derivados de eter sustituido con hexafluoroisopropanol. | |
| RU2013130250A (ru) | Замещенные пуриновые и 7-деазапуриновые соединения | |
| MX2010003224A (es) | Derivados de biaril sulfonamida. | |
| HRP20110807T1 (hr) | Supstituirani pirimidodiazepini korisni kao plk1 inhibitori | |
| RU2012102922A (ru) | Лекарственные соединения и композиции | |
| HRP20110810T1 (hr) | N-[3-fluoro-4-({6-(metiloksi)-7[(3-morfolin-4-ilpropil)oksi]kinolin-4-il}oksi)fenil]-n'-(4-fluorofenil)ciklopropan-1,1-dikarboksamid za liječenje raka | |
| NO2014020I1 (no) | Glykopyrronium eller et salt derav og Indakaterol eller et salt derav i kombinasjon | |
| CY1113395T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη | |
| MX2010003156A (es) | Derivados de aril amida substituida con tetrazol y usos de los mismos. | |
| UA90898C2 (ru) | Способ получения производных пиримидина | |
| HRP20211352T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| MY142474A (en) | 1h-quinazoline-2,4-diones | |
| JP2009503110A5 (enExample) | ||
| MY145838A (en) | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | |
| CN101591280B (zh) | 具有肿瘤诱导分化作用的类维甲酸衍生物及其药物组合物与用途 | |
| ATE371644T1 (de) | Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung | |
| CN106883244B (zh) | 野黄芩素衍生物及其制备方法和应用 | |
| JP2004536132A (ja) | 新規なｅｔ−７４３の抗腫瘍性誘導体 | |
| RU2012120614A (ru) | Новые бацитрациновые антибиотики |